Physician profile
Andrew A Vida
NPI 1831195601
$10,841.09
in general payments reported to CMS, 2019-2025
54 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $852 · 2021: $1,471 · 2022: $1,678 · 2023: $2,007 · 2024: $2,246 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,922.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,382.89 | 2020-2025 | Airsupra, Lokelma, Breztri |
| Novo Nordisk INC | $1,144.39 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $982.45 | 2021-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $900.02 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $857.27 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $643.53 | 2019-2022 | |
| Lilly USA, LLC | $599.61 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.72 | 2019-2024 | Xifaxan |
| Abbvie INC. | $410.08 | 2021-2025 | Qulipta, Vraylar, Linzess |
| Pfizer INC. | $348.08 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $333.66 | 2022-2025 | |
| Glaxosmithkline, LLC. | $283.42 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $226.21 | 2023-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $217.64 | 2019-2023 | |
| Abbott Laboratories | $215.90 | 2022-2025 | Freestyle Libre 3 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Vida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.